Slim: A Potential Cancer Treatment Drug (G23008)

Target Name: KLHDC10

NCBI ID: G23008

KLHDC10

Slim: A Potential Cancer Treatment Drug

KLHDC10, also known as Slim, is a protein that is expressed in the human placenta and has been shown to be involved in the development and maintenance of cancer. The protein is derived from the kallikrein-related heparin gene and has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway.

Slim is a 21-kDa protein that is expressed in the placenta and has been shown to be involved in the development and maintenance of cancer. It is derived from the kallikrein-related heparin gene and has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway.

Slim has been shown to be involved in the regulation of several key signaling pathways, including the TGF-β pathway. This pathway is known to be involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development of cancer.

Slim has been shown to play a role in the regulation of the TGF-β pathway by inhibiting the activity of the transcription factor, SMAD. This protein has been shown to play a role in the regulation of cell signaling pathways and has been shown to be involved in the development of cancer.

In addition to its role in the TGF-β pathway, Slim has also been shown to play a role in the regulation of several other signaling pathways, including the Wnt pathway and theNotch pathway.

Slim has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration and invasion. These processes are important in the development of cancer and are tightly regulated by multiple signaling pathways.

Slim has also been shown to be involved in the regulation of the immune response. This is important in the fight against cancer as it helps to eliminate cells that are derived from mutated or cancerous cells.

In conclusion, KLHDC10, or Slim, as a drug target or biomarker has great potential in the development of cancer treatment. Further research is needed to fully understand the role of Slim in the development and progression of cancer.

Protein Name: Kelch Domain Containing 10

Functions: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948). The CRL2(KLHDC10) complex specifically recognizes proteins with a proline-glycine (Pro-Gly) at the C-terminus, leading to their ubiquitination and degradation (PubMed:29779948). Participates in the oxidative stress-induced cell death through MAP3K5 activation (PubMed:23102700). Inhibits PPP5C phosphatase activity on MAP3K5 (PubMed:23102700). Acts as a regulator of necroptosis (By similarity)

The "KLHDC10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHDC10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets